PharmaEssentia Corp.

As of June 30, 2026, PharmaEssentia Corp. Sponsored GDR 144A carries a market capitalization of 15.70B, placing it among publicly traded companies globally. Its enterprise value stands at 14.97B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

PharmaEssentia Corp. Sponsored GDR 144A's next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, PharmaEssentia Corp. Sponsored GDR 144A has 415.00M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, PharmaEssentia Corp. Sponsored GDR 144A maintains a current ratio of 5.28, meaning it holds 5.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, PharmaEssentia Corp. Sponsored GDR 144A recorded 43.69M in income tax expense.

As of the close on October 22, 2026, PharmaEssentia Corp. Sponsored GDR 144A's stock has gained approximately 136.62% over the past 52 weeks. The 50-day moving average sits at 40.52, while the 200-day moving average is 27.95.

As of June 30, 2026, PharmaEssentia Corp. Sponsored GDR 144A holds 769.29M in cash and equivalents against 32.10M in total debt, resulting in a net debt position of -767.02M. Total book value stands at 1.16B, with working capital of 855.03M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

PharmaEssentia Corp. Sponsored GDR 144A's most recent stock split took place on July 9, 2026 with a 100:111 split ratio.